JG
ONCT

Jefferies Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Jefferies Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-182
Closed -$20K – 2717
2018
Q4 		$20K Buy
+182
New +$36.4K ﹤0.01% 2082
2013
Q3 		– Sell
-121
Closed -$1.12M – 2250
2013
Q2 		$1.12M Buy
+121
New +$932K 0.01% 722

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group's ONCT Position: Q1 2019 in Review

Jefferies Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 182 shares — an estimated $20K sold.

Jefferies Group first reported a position in ONCT in Q2 2013 and held it in 2 quarters. The position peaked at $1.12M in Q2 2013. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

  • Jefferies Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Jefferies Group sold 182 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $20K.
  • Jefferies Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Jefferies Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.12M in Q2 2013.
  • 35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Jefferies Group's 13F filing for Q1 2019, filed 15 May 2019.